HNSPF
Hansoh Pharmaceutical Group Co Limited$4.25 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $4.25
1 year
−15.0%
from $5.00 · Oct 27
30 days
0.0%
from $4.25
52-week range
$3.83–5.16
−18% from high · low Jun 9
Avg volume 20D
15
Oct 22 spike 300
Short interest
🔒 Subscribers only
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
Signal stack
Where each data set points today.
- TrendRANGE
1% below its 50-day average.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 Clinical trial readout
Results Pending: HS-20093 (Phase 3) — Completed 57d ago
Trial: ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 19, 2026
Clinical Trial
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Phase 3 · COMPLETED
Oct 16, 2026
Trial readout
Results Pending: HS-20093 (Phase 3) — Completed 57d ago
Trial: ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer Sponsor: Hansoh BioMedical R&D Company Phase…
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short